[HT-10] Motor neuron diseases in the era after translational research

[HT-10-3] Oligonucleotide drug for treatment of ALS

Takanori Yokota (Dept.of Neurology and Neurological Science,Tokyo Medical and Dental Univ., Japan)

A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.

1984- Resident in Internal Medicine, Tokyo Medical and Dental University （TMDU）
1985- Resident in Internal Medicine, Musashino Red Cross Hospital
1986- Resident in Neurology, TMDU
1987- Post-graduate research course, Department of Neurology,
Tokyo Medical University
1990- Clinical fellow in Neurology, Tokyo Metropolitan Neurological Hospital
1990- Clinical Research Fellow in Internal Medicine, TMDU
1990- Instructor in Neurology, TMDU
1998- Research Fellow in Bredesen's lab in Burham Institute (CA, USA)
1999- Research Fellow in Bredesen's lab in Buck Center for Aging Research (CA, USA)
2000- Assistant Professor in Neurology, TMDU
2004-present Associate Professor in Neurology, TMDU
2010-present Professor in Neurology, TMDU

Board of Directors: Oligonucleotide Therapeutics Society(OTS)
　　　　　　　　　　Japanese Society of Neurology　
　　　　　　　　　　The Japanese Society for Neuroimmunology